The US Food and Drug Administration (FDA) has accepted BioCryst Pharmaceuticals’ new drug application (NDA) for Orladeyo.

Pharmaceutical Technology Excellence Awards are now open for submissions, and you can download our Research Guide for more ...

The French drugmaker said it would commit at least $20bn in the US through 2030, with the aim to increase R&D and ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to ...

Kaerus Bioscience has received US Food and Drug Administration’s (FDA) designations for KER-0193 to treat Fragile X syndrome ...

Boehringer Ingelheim has entered a multi-year partnership with Tempus AI to progress its cancer treatment pipeline.

A new specialist manufacturing facility in Scotland could soon provide solutions to scaling challenges for vital ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Recipharm has joined forces with ProductLife Group (PLG) to support (bio)pharmaceutical firms in expediting market approval ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

HLS Therapeutics has signed an agreement with Esperion Therapeutics for in-licensing and commercialising the oral ...

Japan’s MHLW has approved Sarepta Therapeutics’ gene therapy Elevidys for treating Duchenne muscular dystrophy (DMD) ...